Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Petit A, Castillo M, Gaspa A, Colomer D, Garcia de Albeniz X, Moreno C, Camos M, Mellado B, Mallofre C. Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma. Histopathology. 2009 Aug;55(2):230-2. doi: 10.1111/j.1365-2559.2009.03342.x